NovoLISA (de Novo protein-Linked Instantaneous Solution-based Assay) Platform for Life Sciences Research and Diagnostics
Monod Bio, a life sciences company using AI to generate new proteins for the research use only (RUO) and in vitro diagnostics (IVD) markets, announced the launch of the NovoLISA, a rapid biosensor assay platform that delivers results in just 15 minutes—drastically reducing the time to result when compared with alternative methods, such as the ELISA assay platform often used in RUO settings. The name of the platform, NovoLISA, stands for “de Novo protein-Linked Instantaneous Solution-based Assay”. The Company is launching the NovoLISA platform with its first offering of a C-Reactive Protein (CRP) assay.
The NovoLISA combines two proprietary technologies: the LuxSit™ Pro luciferase reporter and de novo binding protein reagents. This combination forms a uniquely fast assay with an easy-to-use format. Key features of the new NovoLISA platform include 1) results in 15 minutes or less, 2) simple, one step, no wash protocol, 3) no need for sample preparation, and 4) a readout in the common laboratory luminescence plate reader. Alfredo-Quijano Rubio, Ph.D., CSO and co-founder of Monod Bio, said, “NovoLISA brings a new generation of assays to the laboratory. The AI platform used to develop the de novo binders creates sensors that are very small, highly stable, and have high affinity and sensitivity for targets of interest. We’re excited to combine these with our luciferase technology and bring them to the commercial market.”
Also Read: Culture Biosciences Appoints Chris Williams as Chief Executive Officer
The CRP NovoLISA includes the following components: Split LuxSit™ CRP Biosensor proteins, the LuxSit™ Substrate, assay buffer, and CRP analyte. Upon addition of samples containing CRP, the level of luminescence increases in a dose-dependent manner with minimal background when CRP is absent. This interaction produces rapid results from a simple procedure. Daniel-Adriano Silva, Ph.D., CEO and co-founder Monod Bio, said, “We are thrilled to introduce our second commercial product. This launch is particularly exciting as it combines two of our innovative technologies.
The NovoLISA Platform opens the door to further possible assays. Monod Bio states that the NovoLISA platform is positioned to quickly expand its offerings. The next available biosensors on the platform will be Human Interleukin-6 (IL-6), Tumor Necrosis Factor alpha (TNFalpha), Human Interleukin-2 (IL-2), and Cardiac Troponin I (cTnI). These plans for further expansion demonstrate the Company’s capacity for rapid innovation.
Source: PRNewswire